BDB001 for Solid Tumors

Phase 2

Waitlist Available

Research Sponsored by Birdie Biopharmaceuticals HK Limited

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up approximately up to 1.5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial tests BDB001, a drug that boosts the immune system, in patients with advanced cancers that haven't responded to standard treatments. The drug works by making the immune system more aggressive in attacking cancer cells.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ approximately up to 1.5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~approximately up to 1.5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately up to 1.5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Efficacy as measured by Objective Response Rate

Secondary study objectives

Efficacy as measured by Disease Control Rate

Efficacy as measured by Overall Survival (OS)

Efficacy as measured by Progression-Free Survival (PFS)

+5 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: BDB001Experimental Treatment1 Intervention

BDB001 will be administered intravenously as monotherapy in subjects with histologically-confirmed unresectable or metastatic solid tumors that have progressed on anti-PD-1 or anti-PD-L1 mAb treatment either as monotherapy or in combination with other therapies.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

BDB001

2021

Completed Phase 2

~10

Do I qualify?Apply below to find out